Virotherapy is an approach for the treatment of cancer, in which the replicating virus itself is the anticancer agent. Virotherapy exploits the lytic property of virus replication to kill tumor cells. As this approach relies on viral replication, the virus can self-amplify and spread in the tumor from an initial infection of only a few cells. The success of this approach is fundamentally based on the ability to deliver the replication-competent viral genome to target cells with a requisite level of efficiency. With virotherapy, while a number of transcriptional retargeting strategies have been utilized to restrict viral replication to tumor cells, this review will focus primarily on transductional retargeting strategies, whereby oncolytic viruses can be designed to selectively infect tumor cells. Using the adenoviral vector paradigm, there are three broad strategies useful for viral retargeting. One strategy uses heterologous retargeting ligands that are bispecific in that they bind both to the viral vector as well as to a cell surface target. A second strategy uses genetically modified viral vectors in which a cellular retargeting ligand is incorporated. A third strategy involves the construction of chimeric recombinant vectors, in which a capsid protein from one virus is exchanged for that of another. These transductional retargeting strategies have the potential for reducing deleterious side effects, and increasing the therapeutic index of virotherapeutic agents. Oncogene (2005) 24, 7775-7791.
Introduction
The elucidation of the molecular mechanisms underlying neoplastic transformation and progression has resulted in the understanding that cancer is a genetic disease resulting from the accumulation of a series of acquired genetic lesions. Cancer remains the second leading cause of death in the United States, with the mortality rate essentially unchanged between 1975 and 2000 (Edwards et al., 2002; Weir et al., 2003) . This dismal statistic holds true despite advances in the use of chemotherapy, radiotherapy, and reductive surgery to combat the disease. In cases where the nature of the tumor is more difficult to treat (e.g., lung and brain cancers) or where diagnosis is not possible until very late (e.g., ovarian and pancreatic cancers), these conventional therapies have proven to be ineffective, leading to low survival rates. Furthermore, traditional treatments have been widely associated with undesirable side effects. Based on the recognition that current cancer treatment regimens are generally ineffective, it is apparent that novel therapeutic approaches will be required to obtain significant increases in clinical survival. Therefore, gene therapy has become a rational area of interest to develop new cancer treatment regimens. The existing approaches to gene therapy of cancer can be divided into five broad categories: (1) mutation compensation, (2) molecular chemotherapy, (3) genetic immunopotentiation, (4) genetic modulation of resistance/sensitivity, and (5) oncolytic therapy or virotherapy.
Virotherapy marks the newest approach, in which the replicating virus itself is the anticancer agent. Importantly, the success of all these five approaches is fundamentally based on the ability to deliver the therapeutic gene or replication-competent viral genome to target cells with a requisite level of efficiency. With virotherapy, while a number of transcriptional retargeting strategies have been utilized to restrict viral replication to tumor cells, this review will focus primarily on transductional retargeting strategies, whereby oncolytic viruses can be designed to selectively infect tumor cells. Using the adenoviral vector paradigm, there are three broad strategies useful for viral retargeting (Figure 1 ). One strategy uses heterologous retargeting ligands that are bispecific by binding both to the viral vector as well as to a cell surface target. A second strategy uses genetically modified viral vectors in which a cellular retargeting ligand is incorporated. A third strategy involves the construction of chimeric recombinant vectors, in which a capsid protein from one virus is exchanged for that of another. These transductional retargeting strategies discussed herein have the potential for reducing deleterious side effects and increasing the therapeutic index of virotherapeutic agents.
Oncolytic vector advances
The bulk of completed and ongoing clinical trials have established the safety of administering an assortment of viral and nonviral vectors to cancer patients. In a number of trials, transgene delivery and expression were confirmed as well as tumor response in a subset of patients. For example, the biosafety of a nonreplicating adenoviral vector to deliver and express the p53 tumor suppressor gene has been demonstrated in clinical trials of glioma, ovarian, bladder, and non-small-cell lung cancers (Schuler et al., 2001; Buller et al., 2002; Lang et al., 2003; Pagliaro et al., 2003; Wolf et al., 2004) ; however, limited tumor responses have been noted. Especially noteworthy in this regard was the observation in a clinical trial of ovarian cancer that infectional barriers may have limited overall efficacy (Zeimet and Marth, 2003) . One constraint in effective tumor cell transduction is that most viral vectors employed have been rendered replication-incompetent. In this case, tumor cell infection is a terminal event, such that postinfectional amplification and subsequent infection of neighboring cells do not occur.
One conceptual approach to achieve an amplification effect for transduction is via replication of the delivered viral vector post-infection, resulting in lateral spread of the progeny vector. The use of replicative viruses for cancer therapy (virotherapy) was pursued to address the problem of limited tumor transduction experienced in earlier cancer gene therapy strategies (Alemany et al., 2000a; Kirn et al., 2001) . As exemplified in Figure 2 , virotherapy exploits the lytic property of virus replication to kill tumor cells. As this approach relies on viral replication, the virus can self-amplify and spread in the tumor from an initial infection of only a few cells. Although attempted in the past and abandoned because of toxicity and inefficacy (Sinkovics and Horvath, 1993) , the virotherapy approach has re-emerged with great promise, in large part due to better understanding of virus biology and the ability to genetically modify viruses. With this knowledge, researchers can now design viruses to better replicate in and specifically kill tumor cells.
Attenuated viruses, which have been designed to replicate within specific tissues, have been used in human clinical trials to achieve specific oncolysis of various neoplasms. Such viruses, including adenovirus (Habib et al., 2002; Freytag et al., 2003; Makower et al., 2003; Chiocca et al., 2004; Lu et al., 2004; Galanis et al., 2005) and the herpes simplex virus (Harrow et al., 2004 ; Figure 1 Selective retargeting of adenoviral vectors. Adenoviral particles can be transductionally retargeted to tumor cells, using heterologous targeting ligands that are bispecific in binding to the fiber knob domain and to a tumor-associated antigen. Adenoviral particles can also be retargeted to tumor cells by the genetic incorporation of targeting ligands into capsid proteins. In addition, adenoviral particles can be retargeted to tumor cells by the genetic incorporation of fiber/knob chimeras in which the adenovirus fiber knob is replaced by another adenovirus knob, or in which the entire adenovirus fiber is replaced with an artificial fiber and knob structure Selective retargeting of oncolytic adenoviruses JM Mathis et al Kim et al., 2005; Liu et al., 2005a, b; Parikh et al., 2005; Shillitoe and Pellenz, 2005) , have been employed to this end. An expanded knowledge of the viral life cycle has also allowed researchers to utilize RNA viruses, such as Newcastle disease virus (Baxi et al., 2000; Csatary et al., 2004) , vesicular stomatitis virus (Lichty et al., 2004; Shinozaki et al., 2004; Ebert et al., 2005) , reovirus (Norman et al., 2004) , and sindbis virus Hay, 2004; Tseng et al., 2004a, b; Zhang et al., 2004a, b; Unno et al., 2005) for virotherapy, because they preferentially replicate in tumor cells with defects in the RNA-dependent protein kinase (PKR)/ interferon response pathways, or with an activated Ras pathway. Vesicular stomatitis virus and reovirus oncolytic therapy are discussed in detail by Glen Barber, and Shmulevitz and Lee, respectively, in this issue of Oncogene Reviews. More recently, the parvovirus H-l (Herrero et al., 2004; Raykov et al., 2004) , influenza (Muster et al., 2004) , and measles virus (Anderson et al., 2004; Dingli et al., 2004; Heinzerling et al., 2005; Myers et al., 2005) , have been shown to achieve viral oncolysis of tumor cells in preclinical studies.
Adenoviral agents for oncolytic virotherapy
The adenovirus-based vector has emerged as a leading candidate for in vivo oncolytic virotherapy. Adenoviruses are attractive vectors because they can be produced in high titers, they do not integrate into the host chromosome, and they have a wide tropism. In addition, adenoviral vectors infect both dividing and nondividing cells, have high stability in vivo, and have a high capacity for gene transfer. While adenoviral transfection is efficient, the expression of the transferred gene is transient, as the viral genome remains episomal. Clinical administration of low and intermediate doses of Ad vectors appears to be well tolerated. However, adenoviruses may be limited by hepatotoxicity at high doses in vivo (Christ et al., 2000; Everett et al., 2003) . A key characteristic of any conditionally replicative virus for antitumor therapy is that the candidate vector system possesses the capacity to accomplish effective in vivo gene delivery. To this end, Ad vectors have been employed in a large number of gene therapy approaches. Indeed, their highly efficient in vivo gene delivery capacity sets these agents apart from other vectors. Another beneficial attribute contributing to their employment for antitumor therapy is that adenoviruses possess a lytic life cycle that can be exploited for oncolysis. While adenoviruses do not have a natural predilection to replicate in tumor cells, they can be rendered to do so by several ways. For example, Bischoff et al. (1996) employed a conditionally replicative adenovirus (CRAd) deficient in the E1B early gene to accomplish tumor-specific oncolysis. Such a modification Figure 2 Conditionally replicative virotherapy. In conventional nonreplicative vector-based gene therapy, the vector enters the target cell and expresses the effector gene to kill the tumor cells. In replicative virus-based therapy, after entry, the virus replicates primarily in the infected target cell and kills the cell by cytolysis as a consequence of lytic infection. Then, the released virus infects surrounding target cells. The achievement of this lateral spread is a key event for the effectiveness of replicative virus-based therapy was hypothesized by Onyx, Inc., to make the virus (dl1520 or ONYX-015) replicate only in p53-defective cells (the case in 50% of human tumors); however, this principle has been questioned (Harada and Berk, 1999; Hay et al., 1999; Vollmer et al., 1999) . Nonetheless, significant antitumor activity was demonstrated using ONYX-015 both in vitro and in vivo, using murine models of cancer Portella et al., 2002; Geoerger et al., 2003) . The preclinical potential of CRAds led to their rapid translation into human clinical trials. ONYX-015 has now been tested in a variety of tumors, including recurrent head and neck Nemunaitis et al., 2001) , pancreatic (Mulvihill et al., 2001) , colorectal (Reid et al., 2001) , ovarian (Vasey et al., 2002) , and hepatobiliary (Makower et al., 2003) cancers. Variable clinical responses were observed in these trials although the combination of this agent with chemotherapy demonstrated clear benefits for recurrent head and neck cancer (Khuri et al., 2000; Lamont et al., 2000) . Knowledge of the details of the replication cycle of Ads should make it feasible to develop advanced CRAd systems that achieve therapeutic oncolysis over-and-above that achieved with this first-generation CRAd. For example, it is now known that replication of ONYX-015 is severely hampered compared to wild-type virus, probably due to the late virus mRNA transcription function of the missing E1B-55 kDa protein (Harada and Berk, 1999) .
Retargeting CRAds for cancer therapy
Despite the drawbacks realized with the initial ONYX-015 virus, the stage was set for the design of improved second-generation CRAds selective for tumor cells. These agents include the D24 adenovirus with a 24 base pair deletion in the adenovirus E1A gene, which targets replication to retinoblastoma (Rb) gene-defective tumor cells (Fueyo et al., 2000) . Several other oncolytic adenoviruses have been tested in phase I clinical trials. For example, CV706 is an adenovirus designed to replicate in prostate-specific antigen (PSA)-positive tumor cells, and has shown some positive results in patients with recurrent prostate cancer (DeWeese et al., 2001) . In addition, replicative adenoviruses can also be armed with therapeutic genes to enhance oncolysis (Doronin et al., 2000; Kruyt and Curiel, 2002; Sauthoff et al., 2002) . Ad5-CD/TKrep, which is similar to ONYX-015 but also contains a cytosine deaminase/ HSV-1 TK fusion gene for a combination of virotherapy/suicide therapy, was tested in a phase I trial for recurrent prostate cancer (Freytag et al., 2002) . The replication of this virus combined with double-suicide gene therapy and external beam radiation therapy reduced PSA levels by X25% in seven out of 16 patients, with two patients experiencing clearance of adenocarcinoma at 1-year followup. These results were confirmed in a phase I study of patients with intermediate-to high-risk prostate cancer (Freytag et al., 2003) . A number of CRAd agents have been developed, which harbor the essential E1A gene under the control of tumor-specific promoters/elements, including the alpha-fetoprotein promoter (Hallenbeck et al., 1999) , COX-2 promoter (Yamamoto et al., 2003; Kanerva et al., 2004) , DF3/MUC1 promoter (Kurihara et al., 2000) , midkine promoter (Adachi et al., 2001) , PSA/ PSMA enhancer (Shi et al., 2005) , secretory leukocyte protease inhibitor (SLPI) promoter (Rein et al., 2005) , survivin promoter (Zhu et al., 2005) , human telomerase reverse transcriptase (hTERT) promoter (Irving et al., 2004; Uchino et al., 2005) , and the tyrosinase promoter/ enhancer (Nettelbeck et al., 2002; Banerjee et al., 2004) . The promise of transcriptionally regulated oncolytic adenoviruses is reviewed in depth by Yu in this issue of Oncogene Reviews. Most of these agents have demonstrated remarkable preclinical results in eradicating tumors in xenograft mouse models. Thus, these experiences established the concept that a CRAd agent can accomplish significant antitumor effects.
Tumor cell levels of coxsackie and adenovirus receptor (CAR) limit CRAd infectivity
One of the attractive features of CRAd vectors for oncolytic virotherapy is the unparalleled efficiency of Ad vectors in accomplishing in vivo infection. Indeed, of all of the currently available vector approaches, Ad vectors possess the highest capacity to achieve in vivo infection of tumors. Despite this capacity, the overall efficacy of CRAd-based cancer virotherapy approaches remains limited by suboptimal vector efficiency. Of note, human trials carried out to date have demonstrated relatively inefficient gene transfer to tumor cells in contexts whereby non-CRAd vectors have been employed using in vivo delivery schemas. Indeed, even with the replicative Ad system of ONYX-015 that demonstrated promising antitumor activity in preclinical studies, no clinical effect was noted in 16 patients with ovarian cancer treated intraperitoneally with up to 1 Â 10 11 pfu of the adenovirus daily for 5 days (Vasey et al., 2002) . This discrepancy between poor clinical response and encouraging preclinical studies using current nonreplicative and replicative Ad systems has now been understood to result from a relative paucity of expression of the primary adenovirus receptor, CAR, in primary tumors relative to their cell line counterparts (Dmitriev et al., 1998b; Vanderkwaak et al., 1999; Blackwell et al., 2000; Kanerva et al., 2002; Kim et al., 2002b) . Cancer cells have been specifically shown to be profoundly resistant to Ad infection, based upon a relative paucity of CAR expression on tumor targets (Hemmi et al., 1998; Li et al., 1999; McDonald et al., 1999; Asaoka et al., 2000; You et al., 2001; Kim et al., 2002b; Sachs et al., 2002; Fuxe et al., 2003; Kawashima et al., 2003; Qin et al., 2003) . This observation can be explained by the finding that CAR has been shown to exhibit tumor suppression activity when introduced into tumor cells . On this basis, it has been proposed that gene delivery via CAR-independent pathways may be required to circumvent this key aspect of tumor biology (Haviv et al., 2002; Kawakami et al., 2003; Wu et al., 2004b) . Thus, it is clear that augmenting the gene transfer efficacy of Ad vectors for cancer targets is of fundamental importance with respect to deriving their full benefit in the context of the CRAd therapies.
Modification of vector tropism to circumvent tumor cell CAR deficiency
Native adenoviral tropism is mediated by two capsid proteins, fiber and penton base. These proteins bind to a primary, high-affinity cellular receptor, CAR, and the integrins anb3 and anb5, respectively. Manipulations of these molecular interactions have been made to modify adenoviral tropism by retargeting entry through heterologous entry pathways. Based on the above considerations, a concerted effort has been made to modify adenoviral tropism such that enhancement of tumor cell transduction can be accomplished. Precedents for modifying viral tropism to accomplish enhanced and/ or cell-specific gene delivery were first established using retroviral vectors Nilson et al., 1996) . A number of studies have shown that retroviral cell-binding activity or tropism can be altered by modifications of the viral envelope glycoprotein, which interacts with specific receptors on the cell surface.
One approach has involved the construction of pseudotypes -vectors in which the retroviral genome is coated by the envelope protein of another virus (Sinclair et al., 1997; Arai et al., 1998; Chen et al., 2001; Lee et al., 2001; Hu et al., 2003) . Thus, the virus providing the envelope protein dictates the host range of the pseudotyped particle. Other strategies for achieving cell-specific retargeting of retroviral vectors have involved specific genetic modification of the envelope. This has been accomplished by fusing to the retroviral envelope protein either (1) an antibody (Ab) fragment which recognizes a cell-specific antigen, or (2) a ligand with a cognate receptor on the target tissues. In these instances, the demonstration of infection of human cells through the targeted receptor indicates that it is possible to employ genetic methods to engineer recombinant viral vectors with modified tropism. A rational and more flexible alternative to this approach would be to immunologically crosslink the virus to cell-specific receptors using bispecific Ab conjugates. In this regard, Roux et al. (1989) designed a bispecific crosslinking scheme whereby biotinylated monoclonal antibodies (mAbs) directed against the envelope protein of a murine ecotropic retrovirus (gp70) were bound to mAbs against specific membrane markers of nonpermissive cells via a streptavidin bridge. The bifunctional complex was used to link the retrovirus to the target cell, allowing the successful infection of human cells by means of specific membrane markers such as the major histocompatibility complex class I and class II antigens. This demonstrated that the molecular bridging approach permits ecotropic retroviruses to infect nonpermissive cells, overcoming the lack of specific retroviral receptors by retargeting alternate receptors. Thus, these studies demonstrate the capacity to achieve enhanced and cellspecific gene delivery by modifications of viral tropism.
Consideration of these studies designed to modify retroviral tropism has established the concept that cellspecific transduction may be accomplished with genetic modifications of viral domains dictating entry, or by immunologically retargeted binding. It should thus be possible to achieve a similar end with adenoviral vectors, based upon consideration of adenoviral entry dynamics. Following administration of the adenovirus vector, three distinct, sequential steps are required for expression of the therapeutic gene in target cells: (1) attachment of the adenovirus to specific receptors on the surface of the target cell, (2) internalization of the virus, and (3) transfer of the gene to the nucleus, where it can be expressed. Thus, any attempt to modify the tropism of an adenovirus vector must preserve its ability to perform these three functions efficiently. Furthermore, the modification of adenovirus tropism must be approached with knowledge of the biology of adenovirus infection. In this regard, it has been shown that the globular carboxy-terminal (C-terminal) knob domain of the adenovirus fiber protein is the ligand for attachment to the adenovirus cellular receptor CAR, the first step in infection (Louis et al., 1994; Bergelson et al., 1997 Bergelson et al., , 1998 Hong et al., 1997; Tomko et al., 1997) . A trimeric fiber protein protrudes from each of the 12 vertices of the icosahedral viral particle, where it is attached noncovalently to the penton base (Devaux et al., 1990; Ruigrok et al., 1990) . The amino-terminal fiber tail is separated from the knob domain by a long rod-like shaft comprising a 15-amino-acid residue motif repeated 22 times in human adenovirus types 2 and 5 (Devaux et al., 1990; Ruigrok et al., 1990) . Henry et al. (1994) demonstrated that adenovirus infection can be blocked both by a recombinant adenovirus type 5 (Ad5) trimeric knob expressed in Escherichia coli, and by an antiknob Ab; thus the knob is both necessary and sufficient for virion binding to host cells. Following attachment, the next step in adenovirus infection is internalization of the virion by receptor-mediated endocytosis. This process is mediated by the interaction of Arg-Gly-Asp (RGD) sequences in the penton base with secondary host cell receptors, the integrins anb3 and anb5 (Wickham et al., 1993) . Post-internalization, the virus is localized within the cellular vesicle system, initially in clathrin-coated pits and then in cell endosomes. Acidification of the endosomes allows the virions to escape and enter the cytosol. This step has been hypothesized to occur via a pH-induced conformational change, which causes an alteration in the hydrophobicity of the adenoviral capsid proteins, specifically the penton base, which allows its interaction with the vesicle membrane. Upon capsid disassembly and cytoplasmic transport, the viral DNA localizes to the nuclear pore and is translocated to the nucleus of the host cell. This understanding of adenovirus structure-function and the cellular entry pathway has facilitated attempts to modify the tropism of adenoviral vectors and to permit the targeting of specific cell types.
Transductional retargeting using heterologous targeting adapters
In adapter-mediated retargeting, the tropism of the virus is modified by an extraneous targeting moiety, the ligand, which associates with the Ad virion either covalently or noncovalently. Adapters or adapterligand complexes successfully used for Ad retargeting include bispecific Ab or recombinant ligand conjugates, genetic fusions of single-chain variable fragment (scFv) Ab with CAR, or scFv-scFv diabodies. As an initial means to modify the tropism of adenoviral vectors, bispecific adapter conjugates were employed. In this schema, an anti-fiber-knob Ab is employed to attach to the cell recognition motif of the fiber knob and, importantly, ablates the native tropism determinants. Such an Ab, or Fab derivative, is then conjugated to another moiety, which provides targeting specificity. To this end, receptor ligands such as folate and basic fibroblast growth factor (FGF-2) (Goldman et al., 1997) have been used. In addition, anti-receptor Abs directed against the epidermal growth factor receptor (EGF-R) and other cancer-relevant cell surface markers have been employed (Blackwell et al., 1999) . A bispecific Ab was used to target adenoviral vector infection in vivo specifically to cells expressing angiotensin-converting enzyme (ACE), on pulmonary capillary endothelium (Reynolds et al., 2000) .
While the conjugate adapter ligand approach has proved a useful proof-of-principle method in demonstrating transductional retargeting, the production of such molecules is limited by the generation of a heterogeneous populations and low yields. Thus, more recent efforts to produce heterologous targeting ligands have focused on recombinant bispecific adapter molecules. In one strategy, a recombinant bispecific singlechain Ab was produced that encoded a neutralizing antiadenovirus fiber scFv Ab (S11) fused to an scFv Ab directed against the EGF-R. This fusion protein markedly enhanced the infection efficiency of adenoviral vectors in epidermal growth factor receptor-expressing cell lines . In another study, EGF-R-directed bispecific single-chain Abs enhanced adenovirus-mediated transgene expression and oncolysis in bladder cancer lines (van der Poel et al., 2002) . Bispecific targeting molecules, produced by combining the antifiber scFv S11 Ab and an anti-carcinoembryonic antigen (CEA) svFv, mediated selective and enhanced adenovirus transduction of CEA-expressing tumor cells (Korn et al., 2004) .
In contrast to single-chain Abs directed against the fiber knob, another approach for targeting bispecific ligands to the adenovirus is to use the soluble ectodomain of CAR (sCAR). For example, the use of an adapter consisting of sCAR fused to EGF mediated adenovirus retargeting to EGF receptor-positive cells Wesseling et al., 2001) . Other adapters include the fusion of sCAR to stem cell factor (SCF) for retargeting to c-Kit( þ ) CAR(À) hematopoietic cells (Itoh et al., 2003) and receptor-binding domain of apolipoprotein E (ApoE) for retargeting to human diploid fibroblasts (Kim et al., 2002a) . Use of a bispecific protein containing the sCAR genetically fused to a single-chain Ab specific for c-erbB-2 retargeted adenoviruses to ovarian carcinoma cells (Barker et al., 2003) . Selective retargeting to prostate cancer cell lines was demonstrated using a bispecific Ab against PSMA (Kraaij et al., 2005) . Of note, it has been demonstrated that these types of sCAR fusion proteins are able to retarget adenoviral vectors to their tumor-associated antigens after systemic administration -a crucial feasibility that will allow the targeting of metastatic disease . Adenoviral vectors have a poor record of transgene delivery efficiency through physical barriers such as the epithelium or endothelium. It is of interest that, by using an sCAR-transferrin bifunctional adaptor, Zhu et al. (2004) demonstrated that an adenoviral vector has the capability to be transported across polarized epithelial monolayers of Caco-2 cells (a colon carcinoma cell line) by transcytosis. Incorporation of a bacteriophage T4 fibritin polypeptide provided trimerization of sCAR fusion proteins that, compared with the previous use of a monomeric sCAR protein, resulted in augmented affinity to Ad fiber knob domain and an increased ability to block CAR-dependent Ad infection . This principle was also demonstrated using an isoleucine GCN4 trimerization domain (Kim et al., 2002a) .
Studies with these targeting motifs have demonstrated several key concepts with respect to the capacities of tropism-modified adenoviral vectors. First, using molecular conjugate vectors containing binding-incompetent adenovirus, it has been demonstrated that adenovirus binding and post-internalization steps, such as endosomalysis, can be functionally uncoupled . This principle is critical in the context of retargeting adenovirus through heterologous entry pathways, implying that adenoviral entry can be achieved upon binding to non-native receptors. Second, the magnitude of gene transfer to a given target cell may be correlated to the levels of the receptor present. Thus, gene delivery may be achieved with a relative selectivity based on the relative levels of the cancer marker on normal vs tumor cells. On this basis, it is clear that targeted, cell-specific gene delivery may be achieved. This is especially important in the context of epithelial neoplasms, whereby levels of the primary adenoviral receptor CAR have been shown to be relatively limiting. In this instance, the ability to achieve CAR-independent gene transfer is key to the achievement of transduction efficiencies commensurate with cancer gene therapy applications. A third aspect of the ability to achieve CAR-independent gene transfer is that tumor cells normally refractory to adenoviral vectors can now be transduced. In this regard, retargeted adenoviruses have achieved gene transfer to the normally adenovirus-refractory target cells, such as those derived from Kaposi's sarcoma (Goldman et al., 1997) , glioma , or ovarian carcinoma (Kelly et al., 2000) . By these examples, the dramatic gene transfer augmentations noted could allow the delivery of anticancer genes that would achieve a meaningful antitumor effect. Of note, such augmentation achieved by CAR-independent gene transfer is especially relevant in the context of primary human tumors, in which extreme CAR deficiency has been noted. Thus, the strategy of tropism modification using bispecific conjugate adapter molecules allows dramatic augmentations in gene delivery to tumor targets, with a specificity that would predict an improved therapeutic index.
Genetic transductional retargeting using fiber peptide modifications
Adapter-mediated targeting is rather versatile and technically simple, it may use a wide range of targeting ligands, and it allows for the rapid generation of analytical amounts of targeted complexes and their fast validation. However, it requires the production and purification of at least two different components (the virus and targeting ligand), their subsequent conjugation in a targeting complex, and the purification of that complex from nonreacted components. These requirements substantially complicate the large-scale production of the vector complex, which may result in significant batch-to-batch variations and complicate the regulatory approval of the vector for clinical use. In contrast, genetic retargeting, which is based on the genetic incorporation of the ligand into the Ad capsid results in a one-component, self-assembling, and selfreplicating vector, which, once made and validated, may be amplified to any desired scale.
The first efforts to retarget Ad transduction in a single-component system to expand their tropism beyond the natural receptors focused on the incorporation of peptide ligands into the C-terminus of the fiber protein. For example, the addition of a polylysine motif to the C-terminus of the Ad fiber protein (Yoshida et al., 1998; Shinoura et al., 2000) can increase transduction efficiency, by retargeting Ad transduction to heparin sulfate residues on the surface receptors of multiple cell types. An Ad fiber mutant containing 20 lysine residues added at the C-terminus of the fiber increased the transduction efficiency for malignant glioma cells (Yoshida et al., 1998) . The addition of an RGD motif to the C-terminus of the Ad fiber protein can overcome low CAR expression on target cells, thereby enhancing transduction (Wickham et al., 1997) . Other peptide sequences used for retargeting have included the terminal decapeptide of the gastrin-releasing peptide (GRP), which, when added to the C-terminus of the fiber, was accessible to binding by an anti-GRP to the chimeric protein (Michael et al., 1995) . More recently, the attachment of a 12-amino-acid peptide mimic for transferrin to the C-terminus of the fiber protein retargeted viruses to the transferrin receptor (Joung et al., 2005) . However, a major limitation for the addition of peptide sequences to the C-terminal end of the fiber is that amino acids of 27 or more inhibited trimer formation (Hong and Engler, 1996) , although this limitation may be dependant upon the specific sequence involved.
A second locale for the incorporation of peptides was identified by X-ray crystallography: the HI loop is exposed on the fiber knob, and can incorporate up to 83 amino acids without deleterious effects on viral replication (Belousova et al., 2002) . In vitro, Ad vectors containing RGD peptide sequences in the HI loop of the fiber knob showed a higher level of gene transfer than vectors containing RGD peptide at the C-terminus of the fiber knob (Wu et al., 2002; Koizumi et al., 2003) . Incorporation of the RGD motif to the HI loop was successful in retargeting viruses to a number of tumor cells normally resistant to adenovirus infection, including ovarian (Vanderkwaak et al., 1999; Hemminki et al., 2001) , pancreatic (Wesseling et al., 2001) , meningioma (Dirven et al., 2002) , rhabdosarcoma (Cripe et al., 2001) , and glioma (Grill et al., 2001) . Finally, it was hypothesized that dual modification of the C-terminus and the HI-loop with peptide additions could additively improve gene transfer efficiency. An Ad vector containing an RGD motif in the HI loop and a pK7 (polylysine) motif at the C-terminus of the fiber demonstrated the highest infectivity in both CAR-positive and -negative cells (Wu et al., 2002; Koizumi et al., 2003) .
An interesting variant of the fiber peptide modification approach was taken by Korokhov et al. (2003) . Specifically, the 59-amino-acid-long Fc-binding (Cdomain) of Staphylococcus aureus protein A was genetically incorporated into the Ad5 fiber protein at the C-terminus or the HI-loop. The resulting viral vectors were capable of associating with the Fc domain of Ig. In addition, by genetically fusing the Ig Fc domain with an anti-CD40 targeting scFv or to the CD40L ligand, stable complexes with the protein A-modified Ad vectors were formed, resulting in significant augmentation of gene delivery to CD40-positive target cells. A similar approach was taken by Volpers et al. (2003) , who inserted a 33-amino-acid domain corresponding to the immunoglobulin G (IgG)-binding domain (Z33) from S. aureus protein A into the adenovirus fiber protein. This adenovirus vector was successfully retargeted in vitro to EGF-R-expressing cells, in combination with an EGF-R-specific mAb.
With the addition of retargeting ligands to the adenovirus fiber, there are defined clear size limits with respect to heterologous proteins that can be incorporated (Dmitriev et al., 1998a; Krasnykh et al., 1998; Xia et al., 2000; Belousova et al., 2002; Mizuguchi et al., 2001; Nicklin et al., 2001) , which effectively limited the repertoire of motifs to small peptides. This paradigm has initiated a search for capsid locales permissive of incorporating larger and/or more complex protein moieties. Capsid protein IX (pIX) is a small polypeptide of 140 residues (14.7 kDa) that acts as a cement protein to stabilize hexon-hexon interaction and therefore the capsid structure itself (Colby and Shenk, 1981) . Four trimers of pIX interact with a group of nine hexons (GON) in each facet of the icosahedron (Stewart et al., 1991) , resulting in 240 copies of the protein per virion (van Oostrum and Burnett, 1985; Lehmberg et al., 1999) . In addition, pIX also serves as a transcriptional activator of several viral and cellular TATA-containing promoters, including adenoviral E1a, E4, and major late promoters (Lutz et al., 1997) . Based on the elucidation that the pIX C-terminus is surface exposed (Akalu et al., 1999), pIX was exploited as a locale to incorporate heterologous peptides (namely lysine octapeptide and polylysine) into its C-terminus for targeting purposes . The RGD motif and the c-myc epitope were also successfully fused to pIX and assembled into virions (Vellinga et al., 2004) . The myctagged pIX molecules were readily accessible to anti-myc Abs, although peptide spacers increased this accessibility. Thus far, retargeting via pIX modification still needs to be demonstrated, and may require additional fiber modification for efficient transduction.
Hexon is the largest and most abundant of the structural proteins in the adenovirus capsid. The 720 hexon monomers present in each virion form 240 hexon homotrimers, which in turn form 20 capsid facets, each consisting of 12 hexon homotrimers (Vellinga et al., 2005) . As the most abundant capsid protein, modification to the hexon protein is particularly attractive. However, genetic modification of hexon often results in failure of rescuing viable viruses. Oligonucleotides encoding six histidine residues (His6) were incorporated into different hypervariable regions (HVRs) of the hexon, which are nonconserved among hexons of different serotypes . Successful rescue of the modified viruses provides the potential for transductional retargeting involving hexon modification. The 12 pentons located at the 12 vertices of the adenovirus icosahedral capsid are composed of a heteromeric protein formed from the penton base, a homopentameric protein, noncovalently linked to the fiber. Subsequent to fiber knob binding to CAR, interaction of RGD sequence motifs in the penton base integrins induces endocytosis; deletion of the RGD motif significantly reduces the rate of virus internalization (Shayakhmetov et al., 2005a) . Although little work has been carried out on incorporation of ligands, Einfeld et al. (1999) have demonstrated that highaffinity targeting ligands can function following insertion into the penton base.
Genetic transductional retargeting to avoid liver toxicity
Sequestration of adenoviral particles in the liver is a major problem in gene therapy applications, since it results in hepatotoxicity as a result of particle uptake and transgene expression, as well as activation of the host immune response. In particular, concerns have been raised about the safety and potential hepatotoxicity after systemic adenovirus administration following a patient death on a clinical trial with a replicationdefective adenovirus (Raper et al., 2003) . In this case, it appeared that the Ad vector immediately triggered activation of innate immunity and release of proinflammatory cytokines. In mice, the immune response to Ad consists first of an innate immune response followed by a specific CD8( þ ) cytotoxic T lymphocyte (CTL) response and production of neutralizing Ab. Firstgeneration Ad gene therapy vectors (deleted for the E1A, E1B, and E3 regions and carrying foreign genes under the control of exogenous promoters) induce highlevel innate inflammatory responses within the first 24 h in mice after transduction. Both uptake of the capsid and expression of gene products encoded by the vector contribute to an innate inflammatory response (Schaack, 2005) . In mice injected intravenously with wild-type Ad5, liver viral load and liver enzyme elevation peaked early, at days 2 and 4, respectively, post-infection, before a specific CTL response was detectable . In a non-human primate model, systemic delivery of a helper-dependent Ad vector (containing no viral genes), like first-generation Ad vectors, resulted in acute toxicity consistent with activation of the innate inflammatory response, the severity of which was dose dependent. This result confirmed the hypothesis that Ad-mediated acute toxicity is primarily due to innate immunity and is independent of viral gene expression (Brunetti-Pierri et al., 2004) . However, it is also notable that, in many clinical trials, such as a phase I dose-escalation trial of ONYX-015 performed in patients with liver-predominant gastrointestinal carcinoma in combination with intravenous 5-fluorouracil and leucovorin, no doselimiting toxicity, maximally tolerated dose, or treatment-emergent clinical hepatotoxicity was identified (Reid et al., 2001) . These experiences highlight the limitations of animal studies in predicting human clinical responses, particularly hepatotoxicity.
For these reasons, blockade of liver uptake has become an increased area of research attention, and focus has mainly been on modification of the Ad5 fiber knob. A genetic approach was initially taken to ablate the CAR-binding motif in the Ad5 knob, by mutation of a tyrosine residue at amino acid 477 in the DE loop of the fiber to alanine. Although ablation of CAR recognition could be demonstrated in vitro, surprisingly, this did not change in vivo biodistribution or hepatotoxicity (Alemany and Curiel, 2001 ). The preservation of hepatic uptake may have been due to increased blood circulatory half-life or more likely due to CARindependent infectivity of this virus. However, in adenovirus gene transfer experiments in vivo, a more dramatic modification of the adenovirus fiber knob to eliminate CAR binding did result in a 10-fold decrease of adenovirus hepatotropism and subsequent hepatotoxicity (Yun et al., 2005) . Biodistribution studies in mice have suggested that, with systemic administration of adenovirus, low doses of virus are efficiently taken up in the liver by the Kupffer cell system, whereas high doses saturate these cells and the virus disseminates and infects other cell types (Tao et al., 2001) . Studies on Kupffer cell uptake have demonstrated that the mechanism is CAR independent (Shayakhmetov et al., 2004) . Recently, Shayakhmetov et al. (2005b) demonstrated that coagulation factor IX and complement component C4-binding protein can bind the Ad fiber knob domain and provide a bridge for virus uptake through cell surface heparin sulfate proteoglycans and low-density lipoprotein receptor-related protein. Since the fiber knob is the major determinant of tropism (due to functional binding to different receptors), a major strategy to circumvent the potential hepatotoxicity of Ad5 as well as to expand or alter native Ad5 tropism has been to replace the Ad5 fiber with the fiber from another serotype. This approach has the potential advantage of not only circumventing the liver uptake associated with Ad5 (Alemany et al., 2000b) but also overcoming the CAR-deficient phenotype that inhibits efficient transduction of many tumor cells.
Genetic transductional retargeting using serotype knob replacements
A total of 50 distinct serotypes of human adenoviruses have been identified; these serotypes have been classified into six subgroups (A-F) based on sequence comparisons, each subgroup with different tropisms. Subgroup A adenoviruses include serotypes 12, 18, and 31. Adenovirus serotype 5, the most commonly used serotype for gene therapy applications, is classified as subgroup C, which also includes serotypes 1, 2, and 6. Subgroup B adenoviruses can be divided into subgroup B1 (serotypes 3, 7, 16, 21, and 50) and B2 adenoviruses (serotypes 11, 14, 34, and 35); these display different organ tropisms, suggesting a difference in receptor usage. In this regard, Stevenson et al. (1995) showed that the knob domains of adenoviruses of serotype 5 (subgroup C) and serotype 3 (subgroup B1) bind to different cellular receptors. CD46 was suggested to be a receptor for Ad serotypes 11 and 35, both members of subgroup B2 (Segerman et al., 2003b) . However, discrepancies in CD46 binding between subgroups B1 and B2 suggested the use of an alternative receptor. Blocking experiments confirmed that B2 adenoviruses utilize a different receptor than B1 adenoviruses (Segerman et al., 2003a) . Receptor identity for Ad serotype 3 remains disputed. Short et al. (2004) showed that Ad3 utilizes CD80 (B7.1) and CD86 (B7.2) as cellular attachment receptors; however, Sirena et al. (2004) demonstrated that Ad3 can use CD46 as a receptor.
Based on differences in receptor utilization, it was demonstrated that the native tropism of adenovirus serotype 5 could be altered by genetic incorporation of an alternate fiber knob domain from serotype 3 (Krasnykh et al., 1996) . Replacement of the Ad5 fiber knob domain with that of Ad3 fiber resulted in enhanced cytopathicity of a CRAd to primary melanoma cells, which was at least four orders of magnitude higher than wild-type Ad5 . This transductional enhancement was similar for ovarian cancer cells , renal cancer cells (Haviv et al., 2002) , and squamous cell carcinoma (Kawakami et al., 2003) . Interestingly, the genetic shortening of the Ad5 fiber shaft in an Ad5/3 chimera significantly reduced liver tropism . A D24 CRAd containing an Ad5/3 fiber chimera showed enhanced killing in an orthotopic murine model of peritoneally disseminated ovarian cancer, although some treatment-related toxicities were noted (Raki et al., 2005) . Most recently, the concept of a complex mosaic approach was tested by incorporating the RGD motif into HI loop, at the C-terminus, or both locales of the Ad3 knob, in the context of Ad5/3 chimera fiber in order to retarget simultaneously the Ad vector to integrins and Ad3 receptors (Borovjagin et al., 2005) . This study demonstrated that, suggesting that complex mosaic modification can function via dual-receptor targeting.
Another subgroup B adenovirus used for fiber substitution of Ad5 has been Ad35, as demonstrated by the efficient gene transfer into human CD34( þ ) stem cells (Shayakhmetov et al., 2000) . A variety of Ad5-refractory malignant myeloid and B lymphoid cell lines were highly permissive to transduction by an Ad5 chimera containing an Ad35 fiber shaft and knob (Nilsson et al., 2004) . Biodistribution studies in mice showed extremely low levels of Ad35 uptake in liver, lung, spleen, and bone marrow, while Ad5 displayed high transduction of these organs (Seshidhar Reddy et al., 2003) . Other subgroup B adenoviruses used for fiber substitution of Ad5 include Ad7 (Gall et al., 1996; Miyazawa et al., 1999) and Ad11 (Stone et al., 2005) . Another example of fiber substitution is the replacement of Ad5 fiber with a serotype 16 fiber that enhanced the infectivity of cultured synovial cells by 150-fold (Goossens et al., 2001).
The subgroup D adenoviruses include the largest number of serotypes (serotypes 8-10, 13-20, 22-25, 27-30, 32, 33, 36-39, and 42-49) . The Ad serotype 37 uses sialic acid residues as a receptor, rather than CAR (Arnberg et al., 2002) , and an Ad5 vector with a serotype 37 knob substitution can also use sialic acid as a cellular receptor (Arnberg et al., 2000; Cashman et al., 2004) . However, some studies have also demonstrated that wild-type Ad37 may also use a 50-kDa protein for binding of human conjunctival and cervical carcinoma cells (Wu et al., 2001 (Wu et al., , 2004a . Denby et al. (2004) demonstrated that Ad5 vector containing Ad19p or Ad37 fiber substitutions produced significantly less viral infectivity and transgene expression in liver. A vector construct in which Ad17 fiber substitution replaced Ad2 fiber, increased the binding and efficiency of gene transfer to well-differentiated human airway epithelia compared to wild-type Ad2 fiber (Zabner et al., 1999) .
Ad4 is unusual among adenoviruses, because it is the single known serotype of subgroup E. However, the Ad4 fiber gene has close phylogenetic relationship to subgroup C fiber genes (Gruber et al., 1993) . Importantly, neutralizing Abs developed upon the administration of one Ad serotype do not crossreact with an Ad belonging to a second serotype in a manner that blocks infection and gene expression. This was demonstrated by immunizing with a dose of wild-type Ad5 (subgroup C), Ad4 (subgroup E), or Ad30 (subgroup D) administered intratracheally to mice, followed by an intratracheal administration of a replication-deficient subgroup C-derived vector coding for reporter genes. Gene transfer was inefficient, if there has been prior recent airway administration of the same Ad subgroup. In contrast, effective expression from a second Ad administration was achieved with an Ad vector belonging to a subgroup different from the first Ad administered (Mastrangeli et al., 1996) . These data support the paradigm of alternating Ad vectors derived from different subgroups as a strategy to circumvent antiAd humoral immunity. In an infectivity study, Ad4 showed a specific binding affinity for human hepatoma cells and laryngeal carcinoma cells. In addition, the ability of Ad4 hexon to be expressed in hepatoma, breast cancer, and endothelial cell lines was higher than Ad5 (Zhang et al., 2003) .
Subgroup F adenoviruses (serotypes 40 and 41) are associated with gastrointestinal disease. Uniquely, the Ad40 contains two distinct long and short fibers; the short fiber is unable to recognize CAR, while the long fiber binds CAR. Using Ad5-based vector constructs with chimeric Ad40-derived fibers, composed of either long or short shafts together with CAR binding or nonbinding knobs, Nakamura et al. (2003) showed that the high transduction efficiency observed in the liver and spleen following intravenous administration of adenovirus vector was dramatically reduced by both ablation of fiber-CAR interaction and the use of the Ad40 short fiber shaft. These results also demonstrate that the natural tropism of adenovirus in vivo is influenced not only by fiber-CAR interaction but also by fiber shaft length. An Ad5 vector pseudotyped with the short fiber from serotype 41 also mediated very low liver transduction, identifying another construct detargeted from rat liver in vivo (Nicol et al., 2004) .
Genetic transductional retargeting using xenotype knob replacements
Not as rigorously explored, and perhaps more radical, is an approach entailing the development of Ad xenotypes (Glasgow et al., 2004) . In this scheme, xenotypes are defined as constructs in which the fiber knob of a nonhuman adenovirus is incorporated into the capsid of a human Ad5 vector to confer novel tropism. Nonhuman adenoviruses, including those from avian (Cherenova et al., 2004) , bovine (Baxi et al., 2000; Zhang et al., 2005) , ovine (Voeks et al., 2002) , and porcine (Zakhartchouk et al., 2003; Hammond and Johnson, 2005) hosts, represent an enormous resource in vector design, which could offer alternate cellular entry pathways for adenovirus vectors. Some of these viruses have been developed as gene delivery vectors themselves . For example, a chimpanzee adenovirus, C68, was found to be 36 521 base pairs in length and most similar to subgroup E of human adenovirus, with 90% identity in most human Ad4 open reading frames. Replacing the E1a and E1b genes with a minigene cassette created a replication-defective version of C68; this vector was efficiently transcomplemented by the E1 region of human adenovirus type 5. Importantly, the C68 vector could transduce a number of human and murine cell lines (Farina et al., 2001) . However, the substitution of the Ad5 fiber knob with these various xenotype fiber knobs can provide an efficient means to analyse their tropism in the context of an Ad5 vector that has been rigorously studied and for which molecular methods have been well established .
Previously, the unique tropism of canine adenovirus serotype 2 (CAV-2) (Soudais et al., 2000) was explored to generate an Ad5/CAV-2 chimeric vector, which exhibited profound infectivity enhancement of CARdeficient human tumor cell targets (Glasgow et al., 2004) . Another canine adenovirus strain, serotype 1 (CAV-1), has also been partially characterized. Whereas its cell entry biology has not been described to the extent that has been accomplished for CAV-2, the pathological, structural, biophysical, and serological dissimilarities of CAV1 (Marusyk et al., 1970; Marusyk and Yamamoto, 1971; Marusyk, 1972; Marusyk and Hammarskjold, 1972; Curtis and Barnett, 1983; Kremer, 2004) in comparison to CAV-2 suggest that a distinct underlying tropism may be operational. Recently, an adenoviral xenotype possessing the fiber knob of CAV-1 was constructed, and the tropism of this vector was used to demonstrate a CAR-independent entry pathway distinct from that of both CAV-2 and Ad3. In addition, the gene transfer efficiency of this vector in ovarian cancer cell lines and in patient ovarian cancer primary tissue slice samples was superior relative to all other vectors studied (Stoff-Khalili et al. 2005) .
Another approach in retargeting adenoviruses is the modification of capsid proteins that are compatible with the incorporation of heterologous ligands of greater complexity than simple peptide sequences. Whereas small peptides have been incorporated as described previously at the major capsid proteins penton (Einfeld, 1999) , hexon (Vigne et al., 1999; Wu et al., 2005) and in the HI loop (Dmitriev et al., 1998a; Krasnykh et al., 1998; Xia et al., 2000; Mizuguchi et al., 2001; Nicklin et al., 2001; Belousova et al., 2002) and carboxyterminus of the Ad5 fiber protein (Wickham et al., 1996 (Wickham et al., , 1997 , these regions have not been shown to be suitable for incorporation of molecules with great complexity (Wickham et al., 1997; Belousova et al., 2002) . In addition, the resultant adenovirus vectors often have expanded, rather than restricted, cell recognition, as they do ablate native CAR tropism.
The newest strategy capitalizing on the modular structure of the native Ad5 fiber protein has been the development of knobless fibers, in which modifications are based on the concept of completely replacing the native fiber with an alternative protein capable of providing the trimerization function that the knob usually confers. The removal of the structural constraints imposed by the fiber knob could generate a theoretical universal ligand-presenting molecule, through which an expanded repertoire of incorporable and complex ligands can be incorporated without impinging upon proper capsid incorporation. Several chimeric fibers based on this design criteria have been constructed by utilizing various trimerizing motifs, including the trimerizing domain of Moloney murine leukemia virus envelope glycoprotein , the neck region peptide of human lung surfactant protein D (Magnusson et al., 2001) , and the s1 attachment protein of the mammalian reovirus (Mercier et al., 2004) . In this regard, the bacteriophage T4 fibritin protein has been utilized for fiber replacement , which permitted the incorporation of the CD40 ligand . However, the structural integrity of these fibers is lessened Magnusson et al., 2001 Magnusson et al., , 2002 Henning et al., 2005) and retargeting with these vectors, while CAR-independent and target receptor specific, does not achieve the transduction levels associated with an Ad5 fiber on a CAR-expressing cell Belousova et al., 2003) . To address this point, a chimeric fiber was developed, which contains the Ad5 tail, and Ad5 shaft fused to the 12th coil of the fibritin molecule (Noureddini et al., 2005) . This fiber, demonstrating improved incorporation into the viral capsid, provided a new platform for the genetic incorporation of a stabilized scFv. By genetically incorporating a stabilized scFv into the fiber platform, Hedley et al. (2005) demonstrated selective retargeting to the cognate epitope expressed on the membrane surface of cells.
Imaging analysis for assessment of CRAd agents
All of the initial CRAd clinical trials have clearly validated the safety of using oncolytic adenoviruses for cancer therapy. Yet what these trials failed to ascertain and what remain to be rigorously determined are the crucial functions of CRAds: (1) selective replication and killing, (2) robustness of replication, and (3) spread of the virus. A deeper understanding of CRAd biology will contribute greatly to the advancement and realization of these agents for cancer treatment. Given the lack of true tumor models for the evaluation of replicative adenoviruses (Alemany et al., 2000a; Galanis and Russell, 2001 ) and the value of clinical trials, the acquisition of this information from human patients becomes even more imperative in the development of CRAds.
Limited understanding of CRAd behavior in patients is attributed to lack of a noninvasive imaging system for monitoring replicative agents. Several studies have attempted to address this problem, including a study that utilized positron emission tomography (PET) scanning to detect thymidine kinase as a reporter of oncolytic herpes simplex virus replication (Bennett et al., 2001) . Detection was restricted to infected cells expressing the reporter gene, which does not truly represent the physical distribution of the virus itself. Another study employed soluble human CEA and b-hCG peptide markers as a way to monitor oncolytic measles virus therapy in mice which correlated with therapeutic outcome, but could not show viral localization (Peng et al., 2002) . Using the soluble human CEA marker inserted into the E3A region, virus replication of a chimeric Ad5/3 adenovirus correlated with CEA secretion in vitro and plasma CEA levels in vivo . Other conventional imaging systems for gene therapy have been designed for the detection of transgene expression of reporters such as green fluorescent protein (GFP) (Yang et al., 2000) , luciferase (Bhaumik and Gambhir, 2002) , sodium iodide symporter (Cho et al., 2002) , somatostatin receptor type (SSTR-2) , and thymidine kinase (Liang et al., 2002) . Despite their utility for assessing gene delivery and expression, these reporters by themselves are not suitable for monitoring CRAd activity. The essence of oncolytic virus function is to infect and kill target cells, a concept that is at odds with reporter gene expression. As well, reporter gene expression may not truly represent the underlying level of viral replication and particularly the physical distribution of viral progeny.
No completed clinical trials so far have incorporated a monitoring component into replicative agents and therefore have had to rely on conventional histology of biopsy specimens and analysis of body fluids for the detection of virus. Such static assessments fall short of accurately depicting the dynamic mechanism of replicative agents. The ideal system for monitoring CRAds and other oncolytic viruses should meet a number of criteria. First, the detected signal should correlate with the level of viral replication or progeny production. Second, the signal should be directly associated or packaged with the virions to allow direct physical detection of viral dispersion. Third, the monitoring system needs to be self-perpetual in that produced virions as well as their progeny would be detected, allowing multi-time-point and multi-generational imaging of the total viral load that accrues from the initial dose. Fourth, the approach should minimally disrupt the replication and spread efficiency of the virus. Finally, the detectability should be sufficient for noninvasive imaging of the replication events. Such a system would provide the flexibility for dynamic detection of both viral replication and spread to yield valuable and meaningful data.
The combination of a noninvasive imaging modality with a genetic adenoviral labeling system for detection of replication and progeny localization would provide a powerful means to monitor CRAd function in vivo. Genetic labeling of adenovirus through the fusion of a reporter with a structural protein warrants a number of considerations. First, the incorporation efficiency of a structural fusion protein into virions and hence its copy number per virion should be of sufficiency to give optimal detection of viral particles. An estimate of 20 copies of fluorophores per virion has been reported for adenoviral particle visualization (Glotzer et al., 2001) . Second, fusion with the candidate protein should minimally perturb its cellular localization as well as its normal function. This requirement would maximize the possibility for incorporation and also preserve the function of the protein for viral replication. Third, the structural protein fusion label should provide a signal correlating with viral replication and progeny production.
Based on copy number and reports that incorporated small targeting ligands described above, the capsid protein IX is a potential locale for labeling the adenovirus. Thus, it was hypothesized that pIX would be a suitable locale for incorporating larger reporter proteins such as enhanced GFP (EGFP) or herpes simplex virus type 1 (HSV-1) thymidine kinase (TK). In an adenoviral vector construct that incorporated a fusion between pIX and EGFP, DNA packaging and thermostability were marginally hampered by the modification, while DNA replication, cytopathic effect, and CAR-dependent binding, were not affected. Importantly, the fluorescent label was associated with the virus capsid and conferred a fluorescent property useful in detecting adenoviral particles in flow cytometry, tracking, and tissue sections . This study was confirmed by the generation of a virus encoding the pIX-GFP fusion protein that was efficiently incorporated into the Ad capsid (Meulenbroek et al., 2004) . This virus could be tracked in tissue sections obtained from mice after injection into the tibialis anterior muscle. In this context, HSV-1 TK has been utilized both for molecular chemotherapy cancer gene therapy applications and as an agent in PET-based imaging schemas (Herschman, 2004) . PET imaging has been used to monitor HSV-1 TK gene expression after intratumoral injection of a first-generation recombinant adenovirus used for suicide gene therapy in patients with hepatocellular carcinoma (Penuelas et al., 2005) . A recent report sought to incorporate the HSV-1 TK protein as a fusion to the C-terminus of pIX . In this study, the pIX-TK label associated with the capsid demonstrated direct TK activity in vitro in progeny virions as hypothesized. In addition, infection of cells with an adenovirus containing the pIX-TK fusion protein resulted in TK activity in cells with similar activities on growth inhibition in the presence of GCV as wild-type TK. Importantly, using the pIX-TK fusion protein incorporated within the Ad virions functioned as a reporter gene for microPET imaging. While noninvasive imaging of adenoviral vector biodistribution poses formidable challenges, the genetic adenovirus pIX-labeling system may have an important impact in the field of adenoviral virotherapy.
Concluding remarks
Ideally, cancer-specific transduction of CRAds would result in viral-mediated oncolysis of infected tumor tissues and release of the virus progeny, whereby normal (healthy) tissue would be spared. Given that adenovirus serotype 5-based vectors may have a natural liver tropism, any background transduction in normal tissues (and subsequent liver toxicity) presents a particularly critical problem that warrants development of novel approaches to improve cancer specificity of CRAds. Important in the development of novel virotherapeutic agents will be the identification of model systems that more closely resemble the human clinical disease. For example, using primary ovarian tumor samples, significant variation was noted in CRAd DNA replication between different patient samples . Likewise, the use of an ex vivo model system that involves the evaluation of CRAd toxicity and therapeutic efficacy in thin, precision-cut slices of human primary tumor and liver may more closely predict therapeutic index than traditional cell culture models (Kirby et al., 2004) . While important preclinical in vivo therapeutic studies using CRADs have been derived from human tumor xenograft models in immunodeficient mice, it is critical to develop immunocompetent tumor model systems. In this regard, Hallden et al. (2003) identified a number of mouse tumor cell lines that are permissive for viral replication and show therapeutic effects in syngeneic immunocompetent mouse models. Using the cotton rat, a rodent species that is semipermissive for human Ads, Toth et al. (2005) demonstrated the utility of this in vivo model to test the selectivity, immunogenicity, and efficacy of oncolytic Ad vectors. More recently, cross-species replication of Ad5 was demonstrated in canine cells (Ternovoi et al., 2005) . Since the biological behavior and clinical presentation of certain dog tumors closely resemble those of their human counterparts, these results raise the possibility of exploiting canine models for preclinical analysis of candidate CRAd agents designed for human virotherapy.
The strategy of CRAd tropism modification outlined in this review has allowed dramatic augmentations in gene delivery to tumor targets in vitro, with a specificity that would predict an improved therapeutic index. Indeed, these these tropism-modified CRAd vectors have been employed in murine models of human carcinoma, demonstrating significantly enhanced survival advantage in vivo Irving et al., 2004; Witlox et al., 2004; Tekant et al., 2005) . It is therefore likely that the strategies to alter adenoviral tropism will be of universal relevance for anticancer gene therapy applications involving in vivo gene delivery to patients. As transductional retargeted CRAd agents are just entering clinical trials, the gains in therapeutic efficacy through retargeting strategies should soon become apparent.
